^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF inhibitor

    Related drugs:
    2d
    OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    Idafang (ivonescimab)
    3d
    OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Idafang (ivonescimab)
    4d
    Endostar combined with PD-1 blockade, radiotherapy, GM-CSF, and IL-2 (PRaG 2.0E) for refractory non-small cell lung cancer: a single-arm, phase II clinical trial (PRaG2.0E Study Protocol). (PubMed, Transl Lung Cancer Res)
    Concurrently, recombinant human endostatin (Endostar) induces tumor vascular normalization and alleviates immunosuppression by inhibiting regulatory T cells (Tregs)...The study is registered in ClinicalTrials. gov (NCT06047860).
    P2 data • Journal
    |
    IL2 (Interleukin 2) • CSF2 (Colony stimulating factor 2)
    |
    Endostar (recombinant human endostatin)
    4d
    MEDIAL: Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Centre Hospitalier Universitaire, Amiens | Trial completion date: Jul 2023 --> Jun 2026 | Trial primary completion date: Jul 2023 --> Jun 2026
    Trial completion date • Trial primary completion date • HEOR
    9d
    Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer. (PubMed, Cancer Drug Resist)
    As multi-target combination therapy is an essential strategy for overcoming resistance, we analyze key combination targets - such as vascular endothelial growth factor (VEGF), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and lymphocyte activation gene 3 (LAG-3) - and highlight the clinical success of novel dual-target regimens such as ivonescimab (PD-1/VEGF). Furthermore, we discuss potential approaches to overcoming resistance from both microenvironmental (e.g., targeting cancer-associated fibroblasts or utilizing antibody-drug conjugates) and macroenvironmental (e.g., modulating the microbiota or sex hormones) perspectives. This review provides a forward-looking framework for designing precision- and mechanism-driven combination therapies aimed at converting non-responders into responders.
    Review • Journal
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Idafang (ivonescimab)
    9d
    SMT112-3005: A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3) (2025-521587-35-00)
    P2/3, N=220, Recruiting, Summit Therapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Idafang (ivonescimab)
    9d
    Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer (clinicaltrials.gov)
    P2, N=31, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Idafang (ivonescimab)
    10d
    A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=132, Not yet recruiting, Akeso
    New P2 trial
    |
    Idafang (ivonescimab)
    10d
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (clinicaltrials.gov)
    P2, N=120, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    14d
    Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • Idafang (ivonescimab)
    15d
    Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Oct 2031 --> Apr 2032 | Initiation date: Apr 2026 --> Nov 2026 | Trial primary completion date: Jan 2031 --> Jan 2032
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Idafang (ivonescimab)
    15d
    Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Peking University People's Hospital | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Idafang (ivonescimab)